Daily Endocrinology Research Analysis
Analyzed 183 papers and selected 3 impactful papers.
Summary
A mechanistic study reveals that bempedoic acid directly binds and activates PPARα, redefining its lipid-lowering mechanism. A human-mouse translational study identifies pathogenic TEX14 variants that disrupt intercellular bridges and cause meiotic arrest leading to non-obstructive azoospermia. A large randomized trial shows marine omega-3 supplementation does not reduce fractures and has minimal effects on bone density in generally healthy adults.
Research Themes
- Drug mechanism redefinition in metabolic therapeutics
- Genetic and mechanistic basis of male infertility
- Nutritional supplements and skeletal outcomes
Selected Articles
1. Bempedoic acid directly binds and activates PPARα.
Using transcriptomics, biochemistry, and X-ray crystallography, the authors demonstrate that bempedoic acid directly binds the PPARα ligand-binding domain, stabilizes its active conformation, and induces fatty acid oxidation in hepatocytes and mouse liver. Activation of PPARα target genes occurs independently of ACSVL1 conversion to bempedoyl-CoA, and PPARα is required for BA’s metabolic effects.
Impact: This work redefines the mechanism of a widely used lipid-lowering drug by identifying PPARα as a direct target, with structural and in vivo validation. It provides a mechanistic basis for therapeutic effects and suggests broader applications or drug combinations.
Clinical Implications: Understanding BA as a direct PPARα agonist clarifies its metabolic effects and may inform patient selection, biomarker development, and rational combination therapy (e.g., avoiding duplicative PPARα activation with fibrates or leveraging synergistic pathways). Clinical studies should assess PPARα-dependent benefits and risks in humans.
Key Findings
- BA directly binds the PPARα ligand-binding domain and stabilizes its active conformation (X-ray crystallography).
- BA induces PPARα signaling and fatty acid oxidation in primary hepatocytes and mouse liver.
- PPARα target gene activation by BA occurs independently of ACSVL1-mediated conversion to bempedoyl-CoA.
- BA-driven fatty acid oxidation requires PPARα, establishing a direct mechanistic link.
Methodological Strengths
- Multimodal approach integrating transcriptomics, biochemistry, and X-ray crystallography.
- In vivo validation of metabolic effects in mouse liver alongside primary hepatocyte studies.
Limitations
- Preclinical evidence without direct human clinical outcome data.
- Potential species-specific differences in PPARα signaling and BA pharmacology.
Future Directions: Conduct human translational studies to verify PPARα engagement by BA, explore pharmacogenomic predictors of response, and evaluate safety/efficacy of combinations with other PPAR modulators or lipid-lowering agents.
Bempedoic acid (BA) is a recently approved drug that lowers cholesterol and hepatic lipids, yet its mechanism of action remains incompletely understood. Here, we combine transcriptomic, biochemical, and structural approaches to show that BA directly binds to and activates peroxisome proliferator-activated receptor alpha (PPARα). BA treatment robustly induced PPARα signaling and fatty acid oxidation in primary hepatocytes and mouse liver. Through X-ray crystallography, we uncovered that BA binds to the ligand-binding domain of PPARα and stabilizes its active conformation. BA activated PPARα target genes independently of very-long-chain acyl-coenzyme A (CoA) synthetase (ACSVL1), the liver-enriched enzyme that converts BA to its bempedoyl-CoA form. Notably, BA-mediated induction of fatty acid oxidation required PPARα. Together, this work reveals direct PPARα activation as a key mechanism of BA action, providing a molecular basis for its lipid-lowering effects and suggesting broader therapeutic potential beyond the liver.
2. Pathogenic TEX14 Variants Disrupt Intercellular Bridge Formation, Causing Meiotic Arrest and Non-Obstructive Azoospermia in Humans and Mice.
Exome sequencing in 673 NOA patients identified six novel TEX14 variants across four unrelated men. Functional analyses, including a mouse model carrying an analogous frameshift mutation, showed that TEX14 loss disrupts intercellular bridge formation, causes zygotene-stage meiotic arrest, and leads to NOA, establishing a causal role for TEX14 in human spermatogenesis failure.
Impact: This study expands the genetic architecture of NOA and links a specific cytokinesis-related mechanism to human male infertility with cross-species validation.
Clinical Implications: TEX14 should be considered in genetic testing panels for NOA. Identifying pathogenic variants can inform counseling, prognosis, and decision-making regarding invasive procedures (e.g., micro-TESE).
Key Findings
- Six novel TEX14 variants (three frameshift, two missense, one splice-site) were identified in four unrelated NOA patients.
- Functional validation in a mouse model with an analogous frameshift mutation showed disrupted intercellular bridge formation and zygotene meiotic arrest.
- Reduced TEX14 expression and impaired spermatogenesis were observed in patient and mouse testicular tissues, establishing pathogenicity.
Methodological Strengths
- Large NOA exome-sequencing cohort with Sanger confirmation and appropriate controls.
- Cross-species functional validation including engineered mouse model and expression assays.
Limitations
- Small number of affected individuals carrying TEX14 variants limits prevalence estimates.
- Missense variant pathogenicity requires deeper functional characterization; population diversity was limited to Chinese patients.
Future Directions: Broaden population screening for TEX14 in diverse NOA cohorts, perform systematic functional assays for missense variants, and explore therapeutic strategies targeting intercellular bridge stability.
BACKGROUND: Non-obstructive azoospermia (NOA) is a major cause of male infertility, frequently associated with congenital factors. Nevertheless, the genetic underpinnings of NOA remain largely unclear. OBJECTIVES: This study aimed to identify and characterize novel genetic variants contributing to NOA, with a focus on TEX14, a gene critical for intercellular bridge (ICB) formation during meiosis. MATERIALS/METHODS: Exome sequencing was performed on genomic DNA from a cohort of 673 patients with NOA, 143 individuals with oligozoospermia, and 100 fertile controls. Potentially pathogenic TEX14 variants were identified and confirmed by Sanger sequencing. Functional analysis, including qPCR and Western blot, was performed to assess TEX14 expression levels in patient and mouse testicular samples and the effects of TEX14 variants on spermatogenesis and ICB formation in both mice and humans. RESULTS: We identified six novel TEX14 variants in four unrelated infertile Chinese men, including three frameshift mutations (c.2908dupC, p.Arg970Profs5; c.1881dupA, p.Gly628Argfs8; c.1728_1729del, p.Leu577Argfs*58), two missense mutations (c.1121A>G, p.Tyr374Cys; c.865G>A, p.Glu289Lys), and one splicing mutation (c.417+2T>C). To functionally validate the pathogenicity of the frameshift variant c.2908dupC, a mouse model carrying an analogous mutation (Tex14
3. The Effects of Marine Fatty Acid Omega-3 Supplements on Incident Fractures and Bone Mineral Density in Generally Healthy Adults.
In this large randomized, placebo-controlled ancillary study of VITAL (n=25,871; median 5.3 years), marine omega-3 supplementation (1 g/day EPA+DHA) did not reduce total, nonvertebral, or hip fractures. In a subcohort (n=771), omega-3 produced a small increase in whole-body aBMD without meaningful changes at spine/hip BMD, vBMD, or bone strength indices.
Impact: Provides high-level evidence against prescribing omega-3 solely for fracture prevention in generally healthy adults, refining clinical guidance on bone health interventions.
Clinical Implications: Clinicians should not recommend marine omega-3 supplements specifically to prevent fractures in community-dwelling adults without osteoporosis; focus should remain on proven therapies (e.g., calcium/vitamin D adequacy, antiresorptives/anabolics when indicated, fall prevention).
Key Findings
- No reduction in total fractures (HR 1.02), nonvertebral fractures (HR 1.01), or hip fractures (HR 0.89) with omega-3 vs placebo over 5.3 years.
- Small increase in whole-body aBMD over 2 years (+0.03% vs -0.41%) without effect at spine/hip aBMD, or on vBMD and bone strength indices.
- No serious adverse effects were observed with omega-3 supplementation.
Methodological Strengths
- Randomized, placebo-controlled design with adjudicated fracture outcomes in a very large cohort.
- Dedicated imaging subcohort assessing aBMD and vBMD with standardized protocols.
Limitations
- Participants were not selected for low BMD or high fracture risk, potentially diluting effect size.
- Ancillary design and fixed 1 g/day dose may not capture dose-response or effects in osteoporotic populations.
Future Directions: Evaluate omega-3 dosing, formulations, and targeted high-risk populations (e.g., low BMD, prior fractures), and assess skeletal microarchitecture and falls as complementary outcomes.
Although preclinical studies suggest that omega-3 fatty acids may benefit skeletal health, there are few randomized controlled trials investigating effects of supplemental omega-3 on bone outcomes. This VITamin D and OmegA-3 TriaL (VITAL) ancillary study investigated effects of marine omega-3 (1 g/d; EPA + DHA in a 1.2:1 ratio) vs. placebo supplements on fracture risk and bone density/structure. VITAL is a 2x2 factorial randomized placebo-controlled trial that studied effects of supplemental marine omega-3 fatty acids and/or vitamin D3 vs. placebo on cancer and cardiovascular events. The intervention took place from November 2011 through December 2017; median follow-up was 5.3 yr. The study included 25 871 U.S. men (aged ≥50) and women (aged ≥55) without baseline cancer or cardiovascular disease, not selected for low bone density or fracture history. Primary outcomes were adjudicated incident total, nonvertebral, and hip fractures in the overall cohort. In a subcohort of 771 individuals, we measured 2-yr changes in areal bone mineral density (aBMD) by dual X-ray absorptiometry, and volumetric bone mineral density (vBMD), cortical thickness, and bone strength indices at the radius and tibia by peripheral quantitative computed tomography. Supplemental omega-3 vs. placebo had no effect on total (HR, 1.02; 95% CI, 0.92-1.13; p = .73), nonvertebral (HR, 1.01; 95% CI, 0.91-1.12; p = .80), or hip fractures (HR, 0.89; 95% CI, 0.61-1.30; p = .55). In the subcohort, omega-3 supplementation resulted in a small increase in whole body aBMD (+0.03% vs. -0.41%, p = .006) and no effect on aBMD at the spine or hip, or vBMD or bone strength measures at the radius or tibia. No serious adverse effects were observed. Supplementation with marine omega-3 fatty acids did not reduce incident fracture risk. It led to a small increase in whole body aBMD but had no other effects on BMD or bone strength measures compared to placebo in generally healthy midlife and older adults.